Overview

Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the clinical therapeutic dose in Japanese agitated patients with schizophrenia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine